CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals yesterday announced positive interim results from a Phase 1/2 combination study of romidepsin, Velcade® (bortezomib) and dexamethasone in patients with relapsed or refractory multiple myeloma at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA. Romidepsin is a novel, cyclic peptide, histone deacetylase inhibitor under investigation for the treatment of hematologic malignancies. Additional positive data from a single-agent registration study in cutaneous T-cell lymphoma (CTCL) and from a Phase 2 study in CTCL and peripheral T-cell lymphoma (PTCL) were also presented earlier this week in oral and poster presentations respectively. A New Drug Application submission for romidepsin in CTCL is expected by year-end and a registration study in PTCL is currently recruiting patients.
